STOCK TITAN

Tyra Biosciences (TYRA) grants RSUs and stock options to COO

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Tyra Biosciences Chief Operating Officer Ashar Bhavesh received new equity awards in the form of restricted stock units and stock options. On May 5, 2026, Bhavesh was granted 15,013 RSUs, each representing a right to receive one share of common stock, and 50,295 stock options with an exercise price of $33.93 per share.

According to the vesting terms, one quarter of the RSUs vests on each of the first four anniversaries of May 5, 2026, subject to continued service. For the options, 25% of the shares vest on May 5, 2027 and the remainder vests in equal monthly installments over the following three years, with the options expiring on May 4, 2036.

Positive

  • None.

Negative

  • None.
Insider Ashar Bhavesh
Role Chief Operating Officer
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 50,295 $0.00 --
Grant/Award Common Stock 15,013 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 50,295 shares (Direct, null); Common Stock — 15,013 shares (Direct, null)
Footnotes (1)
  1. Represents restricted stock units ("RSUs") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Includes RSUs. 25% of the shares subject to the option shall vest on May 5, 2027, and 1/48th of the total number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
RSUs granted 15,013 shares Restricted stock units granted to COO on May 5, 2026
Options granted 50,295 options Stock options granted to COO on May 5, 2026
Option exercise price $33.93 per share Exercise price for 50,295 stock options
Option expiration May 4, 2036 Expiration date of COO stock options
RSU vesting schedule 25% annually over 4 years Annual vesting from May 5, 2026 anniversaries
Option vesting start 25% on May 5, 2027 Initial cliff vesting for options
restricted stock units ("RSUs") financial
"Represents restricted stock units ("RSUs") granted on May 5, 2026."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with an exercise price of 33.9300."
exercise price financial
"conversion_or_exercise_price: "33.9300" for the stock option grant."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"1/4 of the total number of RSUs granted vest on each of the first four anniversaries."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ashar Bhavesh

(Last)(First)(Middle)
C/O TYRA BIOSCIENCES, INC.
2656 STATE STREET

(Street)
CARLSBAD CALIFORNIA 92008

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Tyra Biosciences, Inc. [ TYRA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Operating Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/05/2026A15,013(1)A$015,013(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$33.9305/05/2026A50,295 (3)05/04/2036Common Stock50,295$050,295D
Explanation of Responses:
1. Represents restricted stock units ("RSUs") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
2. Includes RSUs.
3. 25% of the shares subject to the option shall vest on May 5, 2027, and 1/48th of the total number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
/s/ Ali D. Fawaz, Attorney-in-Fact05/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Tyra Biosciences (TYRA) report for Ashar Bhavesh?

Tyra Biosciences reported that Chief Operating Officer Ashar Bhavesh received equity awards, including restricted stock units and stock options. These awards are compensation-related grants, not open-market purchases or sales, and vest over several years subject to his continued service with the company.

How many RSUs did Tyra Biosciences grant to COO Ashar Bhavesh?

Ashar Bhavesh received 15,013 restricted stock units (RSUs) on May 5, 2026. Each RSU represents a contingent right to receive one share of Tyra Biosciences common stock, with vesting spread over four years, conditioned on his continued service with the company through each vesting date.

What are the terms of Ashar Bhavesh’s new stock options at Tyra Biosciences (TYRA)?

Bhavesh was granted 50,295 stock options with an exercise price of $33.93 per share. Twenty-five percent vests on May 5, 2027, and the remaining options vest in equal monthly installments over the next three years, expiring on May 4, 2036, subject to continued service.

Are Ashar Bhavesh’s recent Tyra Biosciences equity grants open-market purchases?

No. The Form 4 shows compensation-related grants, not market trades. Both the 15,013 RSUs and 50,295 stock options were awarded at no purchase price, reflecting equity-based compensation that vests over time if Bhavesh remains in continuous service with Tyra Biosciences.

How do the RSUs granted to Tyra Biosciences’ COO vest over time?

The 15,013 RSUs granted to Ashar Bhavesh vest in four equal annual installments. One quarter of the total RSUs vests on each of the first four anniversaries of May 5, 2026, provided he continues to serve Tyra Biosciences through each applicable vesting date.

When do Ashar Bhavesh’s Tyra Biosciences stock options expire?

The stock options granted to Ashar Bhavesh on May 5, 2026 expire on May 4, 2036. This provides a ten-year term during which, once vested, he may choose to exercise the options at the stated $33.93 per-share exercise price, subject to applicable plan rules.